Suppr超能文献

年龄相关性黄斑变性的干细胞治疗趋势

Trends of Stem Cell Therapies in Age-Related Macular Degeneration.

作者信息

Maeda Tadao, Sugita Sunao, Kurimoto Yasuo, Takahashi Masayo

机构信息

Department of Ophthalmology, Kobe City Eye Hospital, Kobe 650-0047, Japan.

Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics Research, Kobe 650-0047, Japan.

出版信息

J Clin Med. 2021 Apr 20;10(8):1785. doi: 10.3390/jcm10081785.

Abstract

Age-related macular degeneration (AMD) is a highly prevalent irreversible impairment in the elderly population worldwide. Stem cell therapies have been considered potentially viable for treating AMD through the direct replacement of degenerated cells or secretion of trophic factors that facilitate the survival of existing cells. Among them, the safety of pluripotent stem cell-derived retinal pigment epithelial (RPE) cell transplantation against AMD, and some hereditary retinal degenerative diseases, has been discussed to a certain extent in clinical studies of RPE cell transplantation. Preparations are in progress for its clinical application. On the other hand, clinical trials using somatic stem cells are also being conducted, though these had controversial outcomes. Retinal regenerative medicine using stem cells is expected to make steady progress toward practical use while new technologies are incorporated from various fields, thereby making the role of ophthalmologists in this field increasingly important.

摘要

年龄相关性黄斑变性(AMD)是全球老年人群中一种高度普遍的不可逆损伤。干细胞疗法已被认为可能是治疗AMD的可行方法,可通过直接替代退化细胞或分泌促进现有细胞存活的营养因子来实现。其中,多能干细胞衍生的视网膜色素上皮(RPE)细胞移植治疗AMD以及一些遗传性视网膜退行性疾病的安全性,在RPE细胞移植的临床研究中已得到一定程度的讨论。其临床应用正在筹备中。另一方面,使用体干细胞的临床试验也在进行中,不过这些试验的结果存在争议。随着来自各个领域的新技术被纳入,利用干细胞的视网膜再生医学有望在实际应用方面稳步推进,从而使眼科医生在该领域的作用日益重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9b/8074076/f03a96d09737/jcm-10-01785-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验